0001610717-23-000274.txt : 20230912
0001610717-23-000274.hdr.sgml : 20230912
20230912160602
ACCESSION NUMBER: 0001610717-23-000274
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230908
FILED AS OF DATE: 20230912
DATE AS OF CHANGE: 20230912
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Symons Julian A.
CENTRAL INDEX KEY: 0001824727
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39617
FILM NUMBER: 231250136
MAIL ADDRESS:
STREET 1: C/O ALIGOS THERAPEUTICS, INC.
STREET 2: ONE CORPORATE DRIVE, 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aligos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001799448
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (800) 466-6059
MAIL ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
X0508
4
2023-09-08
0001799448
Aligos Therapeutics, Inc.
ALGS
0001824727
Symons Julian A.
C/O ALIGOS THERAPEUTICS, INC.
ONE CORPORATE DRIVE, 2ND FLOOR
SOUTH SAN FRANCISCO
CA
94080
true
See Remarks
false
Stock Option (Right to Buy)
0.84
2023-09-08
4
A
0
48000
0
A
2033-09-08
Common Stock
48000
48000
D
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Executive Vice President, Chief Scientific Officer
/s/ Lucinda Y. Quan, as attorney-in fact for Julian A. Symons
2023-09-12